Beta Bionics director granted 16,965-share award
Palasis Maria reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Palasis Maria reported acquisition or exercise transactions in this Form 4 filing.
Beta Bionics, Inc. director Maria Palasis received an equity award of 16,965 shares of Common Stock on May 21, 2026. The grant was issued at no cash cost as a restricted stock unit award under the company’s 2025 Equity Incentive Plan, bringing her direct holdings to 29,397 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 16,965 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
Key Figures
Key Terms
restricted stock unit award financial
2025 Equity Incentive Plan financial
Common Stock financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Beta Bionics (BBNX) report for Maria Palasis?
Was the Beta Bionics (BBNX) insider award an open-market purchase or a grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.